Testing Yangxinshi Tablets to Improve Exercise Ability in Adults Aged 18 to 75 with Chronic Coronary Syndrome

What this Trial Is About

Researchers are evaluating the effectiveness and safety of Yangxinshi tablets for patients with chronic coronary syndrome CCS. This is a prospective, multicenter, randomized, open-label, blinded-endpoint clinical trial including 1200 CCS patients. The study is designed to assess exercise capacity and other health outcomes in this population. Participants will be randomly assigned in a 31 ratio to either an experimental group or a control group. The experimental group will receive Yangxinshi tablets three times a day three tablets each time in addition to their basic medication, while the control group will receive only their basic medication. The treatment period for both groups is 24 weeks. During the study, researchers will measure the primary outcome of the 6-minute walking distance 6MWD after 24 weeks of treatment. Secondary outcomes include assessments using the Borg scale and monitoring of major adverse cardiovascular and cerebrovascular events MACCE at multiple time points during treatment. Participants will be monitored for safety and efficacy throughout the 24-week treatment period.

Yangxinshi Tablet Intervention for Exercise Capacity in Patients With Chronic Coronary Syndrome